The CAA group had significantly lower plasma p‐tau 217 levels than the AD group, consistent with recent AD research that recognized soluble p‐tau as an indicator of the parenchymal amyloid burden and its role in driving the development of insoluble tau aggregates [30]. This evidence concerns the gene MAPT and Alzheimer disease.